DENTSPLY SIRONA (NASDAQ:XRAY) Announces Quarterly Earnings Results

DENTSPLY SIRONA (NASDAQ:XRAY) issued its earnings results on Thursday. The medical instruments supplier reported $0.52 EPS for the quarter, beating the consensus estimate of $0.35 by $0.17, FiscalAI reports. DENTSPLY SIRONA had a negative net margin of 17.06% and a positive return on equity of 18.83%. The company had revenue of $898.00 million during the quarter, compared to analysts’ expectations of $889.93 million. During the same period in the previous year, the company earned $0.52 EPS. The business’s revenue for the quarter was down 4.1% compared to the same quarter last year. DENTSPLY SIRONA updated its FY 2026 guidance to 1.400-1.500 EPS.

Here are the key takeaways from DENTSPLY SIRONA’s conference call:

• Q2 revenue declined: Sales fell 4.1% as reported, or 6.3% on a constant-currency basis, with weakness in CAD/CAM, dental consumables, implants and SureSmile. Adjusted EPS was flat at $0.52, while adjusted EBITDA margins were roughly unchanged only after a $44 million tariff refund.
• DENTSPLY SIRONA maintained its 2026 outlook for revenue of $3.5 billion–$3.6 billion and adjusted EPS of $1.40–$1.50, excluding tariff-related effects. Management expects Q3 revenue and earnings to decline sequentially because of seasonality and planned investments.
• The company said the U.S. recovery remains its top priority, but commercial-force training and dealer expansion are expected to have a larger impact in 2027 rather than this year. Management also acknowledged that the U.S. is currently lagging competitors in implants and that SureSmile remains pressured.
• Management reported progress on its 24-month Return-to-Growth plan, including expanded dealer partnerships, clinical education, sales-force certification and increased R&D investment, with improvements expected to become more visible in Q4. DS Core adoption and double-digit APAC milling-system growth were cited as encouraging signs.
• Wellspect remained a bright spot, with revenue up 7.1% on continued new-product sales and geographic expansion. Operating cash flow rose to $99 million from $48 million, and the company repurchased 1.3 million shares while continuing to prioritize debt reduction.

DENTSPLY SIRONA Trading Down 4.4%

NASDAQ XRAY traded down $0.61 during trading hours on Thursday, reaching $13.17. The company’s stock had a trading volume of 5,502,740 shares, compared to its average volume of 5,046,330. The firm has a fifty day simple moving average of $11.68 and a 200-day simple moving average of $11.88. The company has a debt-to-equity ratio of 1.52, a current ratio of 1.53 and a quick ratio of 0.98. DENTSPLY SIRONA has a 52 week low of $9.40 and a 52 week high of $14.86. The stock has a market cap of $2.64 billion, a P/E ratio of -4.18, a P/E/G ratio of 1.70 and a beta of 0.85.

Insider Buying and Selling at DENTSPLY SIRONA

In other DENTSPLY SIRONA news, Director Michael J. Barber purchased 15,175 shares of the business’s stock in a transaction dated Thursday, June 11th. The shares were bought at an average price of $9.88 per share, for a total transaction of $149,929.00. Following the completion of the acquisition, the director owned 55,943 shares in the company, valued at approximately $552,716.84. This trade represents a 37.22% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Brian P. Mckeon acquired 10,000 shares of the firm’s stock in a transaction that occurred on Friday, June 12th. The stock was bought at an average price of $10.12 per share, with a total value of $101,200.00. Following the completion of the acquisition, the director directly owned 10,000 shares of the company’s stock, valued at $101,200. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders acquired 35,160 shares of company stock worth $351,179. 0.46% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in shares of DENTSPLY SIRONA in the 1st quarter valued at about $26,000. Goldman Sachs Group Inc. raised its position in shares of DENTSPLY SIRONA by 827.3% during the first quarter. Goldman Sachs Group Inc. now owns 2,434,925 shares of the medical instruments supplier’s stock worth $36,378,000 after acquiring an additional 2,172,343 shares during the last quarter. Empowered Funds LLC raised its position in shares of DENTSPLY SIRONA by 8.8% during the first quarter. Empowered Funds LLC now owns 16,324 shares of the medical instruments supplier’s stock worth $244,000 after acquiring an additional 1,320 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of DENTSPLY SIRONA by 7.5% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 593,021 shares of the medical instruments supplier’s stock worth $8,860,000 after acquiring an additional 41,579 shares during the period. Finally, Focus Partners Wealth boosted its holdings in DENTSPLY SIRONA by 59.1% in the first quarter. Focus Partners Wealth now owns 25,181 shares of the medical instruments supplier’s stock valued at $376,000 after acquiring an additional 9,355 shares during the last quarter. 95.70% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on XRAY shares. Weiss Ratings reissued a “sell (e+)” rating on shares of DENTSPLY SIRONA in a research note on Monday. Barclays decreased their target price on DENTSPLY SIRONA from $12.00 to $9.00 and set an “underweight” rating on the stock in a research report on Thursday, June 4th. Mizuho lowered their target price on DENTSPLY SIRONA from $16.00 to $14.00 and set a “neutral” rating for the company in a research note on Wednesday, May 6th. BMO Capital Markets began coverage on shares of DENTSPLY SIRONA in a report on Wednesday, July 8th. They issued a “market perform” rating and a $12.00 target price for the company. Finally, UBS Group reduced their price target on shares of DENTSPLY SIRONA from $18.00 to $17.00 and set a “buy” rating on the stock in a research note on Thursday, May 7th. Three research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $13.46.

DENTSPLY SIRONA Company Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.